Greenland Mines (NASDAQ: GRML) is executing a strategic pivot to become a dedicated rare earths and critical minerals company, announcing plans to spin off its biotechnology division in the fourth quarter of 2026. The move follows a series of corporate milestones, including Nasdaq approval of its listing compliance and the completion of the Sarfartoq project acquisition.
The company’s transition comes as it sharpens its focus on supplying materials essential for modern technologies, particularly neodymium-praseodymium (NdPr) oxides used in permanent magnets for electric vehicles and wind turbines. The Sarfartoq project in southwest Greenland, acquired on Sept. 1 with approval from the Government of Greenland, is central to this strategy. An independent S-K 1300 Initial Assessment for the ST1 deposit revealed a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%.
Greenland Mines projects that annual NdPr oxide production from ST1 would equal roughly 34% of current refining outside China, based on 2025 consumption levels, during each of the project’s nine scheduled operating years. This underscores the company’s potential role in diversifying the global supply chain for critical minerals, which is currently dominated by China.
The company also announced board changes, with Riad El-Dada and Dr. Shalom Hirschman stepping down, and Jason Hawkins, a capital markets veteran, joining as Greenland Mines advances the Sarfartoq and Skaergaard projects. The Skaergaard project in southeast Greenland is a palladium-gold-platinum deposit, adding to the company’s multi-asset portfolio.
Greenland Mines’ strategy is built on establishing a North Atlantic Critical Metals Corridor, linking Greenland’s resources with allied downstream jurisdictions and industrial infrastructure. This vision aligns with broader geopolitical efforts to secure supply chains for critical minerals, which are vital for national security and clean energy transitions.
The biotech division, which includes Klotho’s KLTO-202 treatment for amyotrophic lateral sclerosis (ALS), will be spun off to shareholders, allowing the company to focus entirely on mining and processing opportunities. This separation is expected to unlock value in both entities, as each can pursue its own strategic objectives.
The company’s full press release can be viewed at https://ibn.fm/QN1U9. For more information on Greenland Mines, visit the company’s newsroom at https://ibn.fm/GRML.
This strategic realignment positions Greenland Mines to capitalize on the growing demand for rare earth elements, which are critical for the transition to green energy and advanced technologies. By focusing on its mining assets, the company aims to become a significant player in the market, strengthening supply chains that are increasingly under scrutiny for their dependence on a single source.
